We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$21M
(+22%)
Cap. Flow
+$284M
Cap. Flow
% of AUM
244.1%
Top 10 Holdings %
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$4.59M |
| 2 |
Biogen
BIIB
|
+$3.56M |
| 3 |
Cal-Maine
CALM
|
+$2.79M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$2.48M |
| 5 |
Apple
AAPL
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$4.11M |
| 2 |
Gilead Sciences
GILD
|
+$2M |
| 3 |
IBM
IBM
|
+$1.48M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$930K |
| 5 |
Expedia Group
EXPE
|
+$914K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 41.4% |
| 2 | Technology | 6.27% |
| 3 | Consumer Staples | 4.14% |
| 4 | Consumer Discretionary | 2.26% |
| 5 | Materials | 1.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
CALL
Larimar Therapeutics
LRMR
$384M
| $53K | 0.05% |
3,833
-4,650
| -55% | -$368K |
|
202
CALL
TJX Companies
TJX
$171B
| $52K | 0.04% |
+80,000
| New | +$3.05M |
|
|
TWX
203
PUT
DELISTED
Time Warner Inc
TWX
| $52K | 0.04% |
+5,000
| New | +$370K |
|
204
CALL
Macy's
M
$6.23B
| $46K | 0.04% |
40,400
+30,400
| +304% | +$1.09M |
|
|
STJ
205
CALL
DELISTED
St Jude Medical
STJ
| $46K | 0.04% |
+28,800
| New | +$2.05M |
|
206
PUT
Adobe
ADBE
$94.3B
| $45K | 0.04% |
+30,000
| New | +$2.88M |
|
|
207
PUT
Macy's
M
$6.23B
| $45K | 0.04% |
+12,500
| New | +$448K |
|
208
PUT
Procter & Gamble
PG
$349B
| $45K | 0.04% |
+15,000
| New | +$1.23M |
|
|
ENDP
209
PUT
DELISTED
Endo International plc
ENDP
| $44K | 0.04% |
+20,000
| New | +$414K |
|
|
K
210
PUT
DELISTED
Kellanova
K
| $43K | 0.04% |
42,600
+41,428
| +3,535% | +$2.97M |
|
211
PUT
Trip.com Group
TCOM
$26.7B
| $43K | 0.04% |
6,200
-7,800
| -56% | -$340K |
|
212
PUT
Qualcomm
QCOM
$181B
| $42K | 0.04% |
+16,400
| New | +$864K |
|
213
Oracle
ORCL
$364B
| $41K | 0.04% |
+1,000
| New | +$39.9K |
|
|
RAD
214
CALL
DELISTED
Rite Aid Corporation
RAD
| $41K | 0.04% |
1,500
| – | – |
|
215
CALL
Edgewell Personal Care
EPC
$1.37B
| $40K | 0.03% |
+10,000
| New | +$808K |
|
216
CALL
Alnylam Pharmaceuticals
ALNY
$35.7B
| $39K | 0.03% |
35,000
-5,000
| -13% | -$315K |
|
217
CALL
InterDigital
IDCC
$6.73B
| $37K | 0.03% |
+12,800
| New | +$724K |
|
218
PUT
Johnson & Johnson
JNJ
$609B
| $37K | 0.03% |
+228,700
| New | +$26M |
|
|
CYBR
219
PUT
DELISTED
CyberArk
CYBR
| $35K | 0.03% |
16,200
+1,000
| +7% | +$43.2K |
|
|
POT
220
PUT
DELISTED
Potash Corp Of Saskatchewan
POT
| $35K | 0.03% |
+50,000
| New | +$837K |
|
|
DD
221
CALL
DELISTED
Du Pont De Nemours E I
DD
| $35K | 0.03% |
27,100
-58,100
| -68% | -$3.82M |
|
222
ASML
ASML
$671B
| $33K | 0.03% |
+334
| New | +$32.5K |
|
223
PUT
Best Buy
BBY
$18B
| $32K | 0.03% |
+15,000
| New | +$472K |
|
|
SAGE
224
CALL
DELISTED
Sage Therapeutics
SAGE
| $32K | 0.03% |
+15,300
| New | +$510K |
|
|
LLTC
225
PUT
DELISTED
Linear Technology Corp
LLTC
| $32K | 0.03% |
11,900
+10,100
| +561% | +$462K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q2 2016 Portfolio in Review
As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.
- FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
- FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
- FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
- FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
- FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
- FT Options opened 171 new positions and closed 122 in Q2 2016.
- FT Options's portfolio value rose 22% quarter-over-quarter to $116M.
Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.